CA2520960A1 - Use of atii antagonist for the treatment or prevention of metabolic syndrome - Google Patents
Use of atii antagonist for the treatment or prevention of metabolic syndrome Download PDFInfo
- Publication number
- CA2520960A1 CA2520960A1 CA002520960A CA2520960A CA2520960A1 CA 2520960 A1 CA2520960 A1 CA 2520960A1 CA 002520960 A CA002520960 A CA 002520960A CA 2520960 A CA2520960 A CA 2520960A CA 2520960 A1 CA2520960 A1 CA 2520960A1
- Authority
- CA
- Canada
- Prior art keywords
- angiotensin
- receptor antagonist
- type
- treatment
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *Cc(cc1)ccc1-c1ccccc1-c1nnn[n]1 Chemical compound *Cc(cc1)ccc1-c1ccccc1-c1nnn[n]1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0300988-3 | 2003-04-03 | ||
| SE0300988A SE0300988D0 (sv) | 2003-04-03 | 2003-04-03 | New use |
| PCT/SE2004/000505 WO2004087136A1 (en) | 2003-04-03 | 2004-03-31 | Use of atii antagonist for the treatment or prevention of metabolic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2520960A1 true CA2520960A1 (en) | 2004-10-14 |
Family
ID=20290927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002520960A Abandoned CA2520960A1 (en) | 2003-04-03 | 2004-03-31 | Use of atii antagonist for the treatment or prevention of metabolic syndrome |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20060194856A1 (https=) |
| EP (1) | EP1613309A1 (https=) |
| JP (1) | JP2006522115A (https=) |
| KR (1) | KR20050114671A (https=) |
| CN (1) | CN1771033A (https=) |
| AU (1) | AU2004226517B2 (https=) |
| BR (1) | BRPI0408979A (https=) |
| CA (1) | CA2520960A1 (https=) |
| IL (1) | IL170706A0 (https=) |
| MX (1) | MXPA05010660A (https=) |
| NO (1) | NO20054370L (https=) |
| NZ (1) | NZ542640A (https=) |
| SE (1) | SE0300988D0 (https=) |
| WO (1) | WO2004087136A1 (https=) |
| ZA (1) | ZA200507945B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008067378A2 (en) * | 2006-11-28 | 2008-06-05 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted phenyltetrazoles |
| JP2015509969A (ja) * | 2012-03-16 | 2015-04-02 | グルソックス・バイオテック・アーベー | Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| GB9406573D0 (en) * | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
| DE4439947A1 (de) * | 1994-11-09 | 1996-05-15 | Boehringer Mannheim Gmbh | 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| NZ509260A (en) * | 1998-07-10 | 2003-09-26 | Novartis Ag | Pharmaceutical composition containing valsartan and a calcium channel blocker |
| IL152081A0 (en) * | 2000-04-12 | 2003-05-29 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| CA2420055C (en) * | 2000-08-25 | 2010-06-01 | Takeda Chemical Industries, Ltd. | Fibrinogen-lowering agent |
| US8168616B1 (en) * | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US20030092736A1 (en) * | 2001-05-30 | 2003-05-15 | Cheng Peter T. | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| EP1579872B8 (en) * | 2002-12-27 | 2012-11-07 | Takeda Pharmaceutical Company Limited | Body weight gain inhibitor |
-
2003
- 2003-04-03 SE SE0300988A patent/SE0300988D0/xx unknown
-
2004
- 2004-03-31 EP EP04724927A patent/EP1613309A1/en not_active Ceased
- 2004-03-31 AU AU2004226517A patent/AU2004226517B2/en not_active Ceased
- 2004-03-31 CN CNA2004800093941A patent/CN1771033A/zh active Pending
- 2004-03-31 KR KR1020057017718A patent/KR20050114671A/ko not_active Ceased
- 2004-03-31 US US10/550,760 patent/US20060194856A1/en not_active Abandoned
- 2004-03-31 MX MXPA05010660A patent/MXPA05010660A/es active IP Right Grant
- 2004-03-31 NZ NZ542640A patent/NZ542640A/en not_active IP Right Cessation
- 2004-03-31 CA CA002520960A patent/CA2520960A1/en not_active Abandoned
- 2004-03-31 JP JP2006507997A patent/JP2006522115A/ja active Pending
- 2004-03-31 WO PCT/SE2004/000505 patent/WO2004087136A1/en not_active Ceased
- 2004-03-31 BR BRPI0408979-0A patent/BRPI0408979A/pt not_active IP Right Cessation
-
2005
- 2005-09-06 IL IL170706A patent/IL170706A0/en unknown
- 2005-09-21 NO NO20054370A patent/NO20054370L/no not_active Application Discontinuation
- 2005-09-30 ZA ZA200507945A patent/ZA200507945B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060194856A1 (en) | 2006-08-31 |
| MXPA05010660A (es) | 2005-12-12 |
| IL170706A0 (en) | 2009-02-11 |
| NZ542640A (en) | 2008-06-30 |
| AU2004226517A1 (en) | 2004-10-14 |
| NO20054370D0 (no) | 2005-09-21 |
| AU2004226517B2 (en) | 2008-01-24 |
| ZA200507945B (en) | 2007-04-25 |
| WO2004087136A1 (en) | 2004-10-14 |
| CN1771033A (zh) | 2006-05-10 |
| KR20050114671A (ko) | 2005-12-06 |
| BRPI0408979A (pt) | 2006-04-04 |
| JP2006522115A (ja) | 2006-09-28 |
| EP1613309A1 (en) | 2006-01-11 |
| NO20054370L (no) | 2005-10-31 |
| SE0300988D0 (sv) | 2003-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8865650B2 (en) | Therapy for complications of diabetes | |
| JP5425631B2 (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト | |
| US20060167045A1 (en) | Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist | |
| US20070293552A1 (en) | Antihypertensive therapy method | |
| US20100105746A1 (en) | Method for treating metabolic diseases | |
| AU2004226517B2 (en) | Use of ATII antagonist for the treatment or prevention of metabolic syndrome | |
| JP2018521077A (ja) | 糖尿病性腎症を治療するためのｐｄｅ４阻害剤 | |
| KR20200009101A (ko) | 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제 | |
| AU2012346754B2 (en) | Pharmaceutical composition for preventing or treating hyperlipidemia | |
| JP2009256209A (ja) | 降圧療法 | |
| WITTENBERG¹ et al. | Long-Term (12-Month) Antihypertensive, Metabolic, and Renal Hemodynamic Effects of | |
| CA2677822A1 (en) | Antihypertensive drug combination | |
| HK1180956A (en) | Therapy for complications of diabetes | |
| NZ625006B2 (en) | Pharmaceutical composition for preventing or treating hyperlipidemia | |
| KR20150068864A (ko) | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |